|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mirvetuximab Soravtansine, IMGN853, is an ADC targeting the folate receptor alpha (FRα) and has demonstrated promising single agent activity and a favorable toxicity profile in FRα-positive, platinum-resistant, epithelial ovarian cancer (EOC).
|
30531606 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
New tumor markers, such as PRSS8, FOLR1, KLK6/7, GSTT1, and miRNAs, are getting ahead and are worth noting for early detection of ovarian cancer.
|
31081307 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
One new molecular target in epithelial ovarian cancer is folate receptor alpha (FRα).
|
30635448 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our previous identification of degenerate HLA-class II epitopes from human FR led to the development of a broad coverage epitope pool potentially useful in augmenting antigen-specific immune responses in most patients.<b>Patients and Methods:</b> We conducted a phase I clinical trial testing safety and immunogenicity of this vaccine, enrolling patients with ovarian cancer or breast cancer who completed conventional treatment and who showed no evidence of disease.
|
29545464 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer.
|
30107179 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
FOLR1 may be a useful biomarker for ovarian cancer, and it may be useful as a therapeutic application to improve sensitivity to cisplatin treatment.
|
29433550 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
KD-10 tumor xenografts in severe-compromised immune-deficient mice were likewise sensitive to <b>AGF94</b> Collectively, our results demonstrate the substantial therapeutic potential of novel 6-substituted pyrrolo[2,3-<i>d</i>]pyrimidine antifolates with dual targeting of PCFT and FRα toward EOCs that express a range of FRα, along with PCFT, as well as cisplatin resistance.<i></i>.
|
28138029 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Folate binding protein(FBP) is an immunogenic protein over-expressed in endometrial(EC) and ovarian cancer(OC).
|
27852036 |
2017 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, FRα-targeted lipoplexes with therapeutic gene expression regulated by an hTERT promoter might be a promising gene therapy agent and a potential translational candidate for the clinical treatment of ovarian cancer.
|
27026065 |
2016 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
RNA scope, a novel chromogenic in situ hybridization assay tool, was used to examine expression of the alpha (FOLR1) and beta (FOLR2) isoforms of folate receptor relative to each other as well as to the macrophage markers CD11b and CD68, in samples of normal fallopian tube and fallopian adenocarcinoma as well as normal ovary and EOC.
|
25971554 |
2015 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Folate receptor alpha (FRalpha) is overexpressed on ovarian cancer cells and is a promising molecular target for ovarian cancer gene therapy, but there was still no related report.
|
23802413 |
2013 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study was to measure the levels of FOLR1 and Dkk-3 in the serum of patients with ovarian cancer, benign gynecological conditions and healthy women.
|
23528302 |
2013 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
While few differences were observed in the expression profiles of genes in the 1-carbon cycle, genes previously considered to be overexpressed in EOC (e.g., FOLR1, MSLN, MUC16 and HE4) showed significantly increased expression when comparing EOC to normal ovary.
|
23880844 |
2013 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
The chimeric antibody, MOv18 IgE, against the human ovarian carcinoma antigen, folate receptor α (FRα), is more effective than its IgG1 counterpart in xenograft models of ovarian cancer.
|
21569129 |
2011 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.
|
19454358 |
2009 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Folate receptor alpha as a tumor target in epithelial ovarian cancer.
|
18222534 |
2008 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, the data suggest the possible predictive value of FBP in ovarian carcinoma, as higher levels of expression can be indirectly but significantly associated with increased drug sensitivity.
|
9218736 |
1997 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using the monoclonal antibody (MAb) MOv 18 and cytofluorimetric analysis, we investigated FBP expression in frozen neoplastic tissues from 136 patients diagnosed with epithelial ovarian cancer.
|
9133455 |
1997 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, high affinity folate receptor (FOLR1), which maps to 11q13.3-13.5, is expressed at an elevated level on the surface of over 80% of nonmucinous epithelial ovarian cancers.
|
8094291 |
1993 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
This molecule is a high affinity folate binding protein (FBP) and a potential marker for ovarian carcinoma.
|
8242637 |
1993 |
|
Carcinoma, Ovarian Epithelial
|
0.100 |
Biomarker
|
disease |
BEFREE |
Folate-binding protein is a marker for ovarian cancer.
|
1717147 |
1991 |